Foghorn Therapeutics Inc (FHTX NASDAQ) stock market data APIs
$5.0168
-0.06(-1.2%)
as of March 16, 2026
Try our APIs with
free plan!
Foghorn Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
5.0168
Open
4.9551
High
5.2556
Low
4.9425
52 wk Range
2.9448-6.95
Market Cap
287 M
Shares Outstanding
58 582 K
Revenue
30 909 K
EPS
-0.3654
Beta
3.116
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Foghorn Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Foghorn Therapeutics Inc data using free add-ons & libraries
Get Foghorn Therapeutics Inc Fundamental Data
Foghorn Therapeutics Inc Fundamental data includes:
- Net Revenue: 30 909 K
- EBITDA: -78 775 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-05
- EPS/Forecast: -0.2589
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Foghorn Therapeutics Inc News
New
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potent...
S&P Futures Slip as Bond Yields Climb After Jump in Oil, Key U.S. Jobs Report in Focus
March S&P 500 E-Mini futures (ESH26) are trending down -0.53% this morning as Treasury yields continued to rise after another surge in oil prices stoked concerns that the Middle East conflict would dr...
Stocks Finish Lower as War Rages in the Middle East
The S&P 500 Index ($SPX) (SPY) on Thursday closed down -0.56%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.61%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.29%. March...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Get Foghorn Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
